Business Context and Reporting Period
Company: Skye Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 11, 2022
Event: Entry into a Material Definitive Agreement (Arrangement Agreement) to acquire Emerald Health Therapeutics, Inc. ("EHT").
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain periodic financial statements (e.g., revenue, profit, cash flow, or debt levels). The only specific financial figure disclosed is the termination fee associated with the agreement.
- Termination Fee: CAD $500,000 (payable by either Skye or EHT under specified termination circumstances).
Material Changes and Transaction Terms
On May 11, 2022, Skye Bioscience, Inc. and EHT entered into an Arrangement Agreement to combine the two companies via a plan of arrangement under British Columbia law.
- Consideration: EHT shareholders will receive 1.95 shares of Skye common stock for each EHT share held (Exchange Ratio).
- Options and Warrants: Outstanding EHT options and warrants will be converted into Skye options and warrants, adjusted for the Exchange Ratio, retaining original terms.
- Governance Changes: The Skye Board of Directors will expand to six members at the Effective Time, comprising five existing Skye directors and one existing EHT director (Bobby Rai).
- Support Agreements: Support agreements were executed with certain shareholders of both companies to vote in favor of the transaction.
- Debt Waiver: Emerald Health Sciences, Inc. waived potential events of default under a credit agreement with Skye triggered by this transaction.
Guidance, Outlook, Risks, and Conditions
Conditions to Closing: The transaction is subject to several conditions, including shareholder approvals (majority of Skye; 66 2/3% of EHT votes cast), court approval from the Supreme Court of British Columbia, regulatory approvals, and the absence of material adverse effects.
Timeline: The "Outside Date" for closing is October 15, 2022, extendable by up to 45 days if regulatory or court conditions are not met.
Risks and Contingencies:
- Termination Rights: Either party may terminate if the transaction is not consummated by the Outside Date, if shareholder approval is not obtained, or if a superior proposal is accepted.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks such as clinical trial delays, dependence on third-party manufacturers, and the impact of the COVID-19 pandemic.
- Tax Implications: The transaction is expected to be a taxable exchange for EHT shareholders for U.S. and Canadian federal income tax purposes.
Investor Verification Checklist
- Verify the final approval status of the Arrangement by both Skye and EHT shareholders.
- Confirm receipt of the Final Order from the Supreme Court of British Columbia.
- Review the upcoming Proxy Statement (Schedule 14A) and Management Information Circular for detailed financial projections and risk factors.
- Monitor for any superior proposals that could trigger termination rights or fee payments.
- Check the status of the waiver of default under the credit agreement between Emerald Health Sciences, Inc. and Skye.